FDA approves the first generic naloxone nasal spray to treat opioid overdoses

Cross-posted from Optum Insights blog. On April 19, the U.S. Food and Drug Administration (FDA) approved the first generic for Narcan® Nasal Spray, the life-saving medication used for the emergency treatment of opioid-related overdose. After receiving tentative approval last June, Teva Pharmaceuticals USA Inc. has been granted final approval to market naloxone nasal spray. Teva … Read moreFDA approves the first generic naloxone nasal spray to treat opioid overdoses

Is it just me or are we all thinking the same thing? Is this the beginning of mandatory MSAs in liability, no-fault, work comp claims?

black and white blackboard business chalkboard
Photo by Pixabay on Pexels.com

Late in 2018, our federal government announced that in 2019 that it intends to regulate how and when to take Medicare’s future interests into account.

Read moreIs it just me or are we all thinking the same thing? Is this the beginning of mandatory MSAs in liability, no-fault, work comp claims?

Feds pursuing Medicare conditional payment reimbursement from beneficiaries’ attorneys, as well as primary payers

Although we hear a great deal about Medicare becoming increasingly more aggressive with primary payers (responsible employers, corporations, insurers, self insured entities, and third party administrators), the federal government is also becoming just as unforgiving with beneficiaries’ attorneys. Pursuant to the Medicare Secondary Payer provisions of the Social Security Act, 42 U.S.C. § 1395y(b)(2), when Medicare … Read moreFeds pursuing Medicare conditional payment reimbursement from beneficiaries’ attorneys, as well as primary payers

FDA requires label changes for opioid analgesics to guide prescribers when gradual tapering is needed

This is a crosspost from the Optum Insights blog. The U.S. Food and Drug Administration (FDA) issued a safety communication in early April that requires changes to prescribing information for opioid analgesics used in outpatient settings. The goal is to expand the information available to health care providers and patients when opioid analgesics have been … Read moreFDA requires label changes for opioid analgesics to guide prescribers when gradual tapering is needed